clinical trial · NCT06824467
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 770
Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerSacituzumab tirumotecanBevacizumabH1 receptor antagonistH2 receptor antagonistAcetaminophen (or equivalent)Dexamethasone (or equivalent)Steroid mouthwash (dexamethasone or equivalent)
brief summary
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
started
Apr 9, 2025
primary completion
Apr 27, 2029
completion
Nov 9, 2032
last updated
May 29, 2026
official title
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol